Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of Buy by Analysts

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Rating) have earned an average recommendation of “Buy” from the ten research firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12 month price […]

Related Keywords

,Geode Capital Management ,Goldman Sachs Group Inc ,Analyst Recommendations For Madrigal Pharmaceuticals ,Zacks Investment Research ,Blackrock Inc ,Madrigal Pharmaceuticals Company Profile Get Rating ,Madrigal Pharmaceuticals ,Madrigal Pharmaceuticals Inc ,Nasdaq ,Advisor Group Holdings Inc ,Canaccord Genuity Group ,Barclays Plc ,Get Rating ,Genuity Group ,Investment Research ,Group Holdings ,Sachs Group ,Capital Management ,Pharmaceuticals Company Profile ,Nasdaq Mdgl ,Mdgl ,Medical ,87162t20 ,Ratings ,Consensus ,